Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Bioequivalence study
Status
Ongoing, recruitment ended
Participants planned
32
Countries
1
Sites
1
No medical condition
Key facts
- Sponsor
- Laboratorios Cinfa S.A.
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Not possible to specify
- Trial duration
- 11 May 2026 → ongoing
- Decision date (initial)
- 2026-04-24
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
No medical condition
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Laboratorios Cinfa S.A.
- Sponsor organisation
- Laboratorios Cinfa S.A.
- Address
- Poligono Industrial Areta Carretera Olaz Chipi 10
- City
- Huarte
- Postcode
- 31620
- Country
- Spain
Scientific contact point
- Organisation
- Laboratorios Cinfa S.A.
- Contact name
- Rubén Rubén Estepa Sanz
Public contact point
- Organisation
- Laboratorios Cinfa S.A.
- Contact name
- Rubén Rubén Estepa Sanz
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Czechia | Ongoing, recruitment ended | 32 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Czechia | 2026-05-11 | 2026-05-11 | 2026-05-23 |
Application history
2 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-04-01 | Czechia | Acceptable 2026-04-20
|
2026-04-24 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2026-05-11 | Czechia | Acceptable 2026-04-20
|
2026-05-11 |